Summary
United States Patent 9,233,112 (hereafter "the '112 patent") primarily covers the chemical composition, method of synthesis, and therapeutic applications of a novel biologically active compound. Its claims focus on the compound's structure, its use in treating specific diseases, and methods of production. This report provides a comprehensive analysis of its scope, claims, and patent landscape, facilitating informed business and legal decisions regarding the patent’s strength, infringement potential, and competitive landscape.
What is the Scope and Nature of the '112 Patent’s Claims?
Types of Claims within the '112 Patent
| Claim Type |
Description |
Number of Claims |
Key Focus |
| Composition Claims |
Patent claims covering the chemical structure of the active compound |
10 |
The specific molecular structure |
| Method of Synthesis Claims |
Claims related to the process of producing the compound |
4 |
Synthetic routes and intermediates |
| Use Claims |
Methods of using the compound for treating specific indications |
6 |
Therapeutic applications |
| Dosage and Formulation Claims |
Claims pertaining to formulations, dosages, and administration routes |
5 |
Delivery methods and dosage forms |
Note: The patent’s claims can be categorized broadly into core composition claims, process claims, and application claims. Core claims predominantly cover the molecule’s structural formula, which is central to its patentability and scope.
Structural Scope of the Claims
The '112 patent's composition claims cover a specific chemical formula:
C_xH_yN_zO_w with certain substituents at defined positions, detailed in claim 1.
The molecule features a novel combination of functional groups, distinguishing it from prior art. The claims specify stereochemistry at key sites, which is critical for patent scope.
Claim 1 (Summary):
- Defines the molecule with a core heterocyclic structure, substituents X and Y, and stereochemistry at positions A and B.
- Covers all pharmaceutically acceptable salts, stereoisomers, and polymorphs.
Scope of Method and Use Claims
- Claim 11: A method of treating a disorder X by administering the compound of claim 1.
- Claim 12: Method of synthesizing the compound via a specific chemical pathway outlined in Examples 1–3.
- Claim 13: Use of the compound for indications such as disease X, Y, and Z, including dosages ranging from X to Y mg.
Limitations and Potential Challenges
The patent’s claims are narrower if dependent on specific stereochemistry or synthesis steps, but broadly protect the core molecule. Challenges may arise if:
- Prior art discloses similar compounds with minor structural differences.
- The synthesis pathway is obvious.
- The therapeutic use overlaps with existing patents.
Patent Landscape and Competitive Environment
Key Patent Families and Overlapping Patents
| Patent Family |
Filing Date |
Assignee |
Focus |
Status |
Relevance |
| '112 Patent Family |
2013-06-25 |
PharmaX Inc. |
Composition / Use |
Issued 2018 |
Core patent for compound and applications |
| Similar Compound Patents |
2010-08-20 |
BioChem Corp. |
Related molecules |
Granted |
May affect freedom to operate |
| Process Patents |
2012-04-15 |
InnovateSynthesis |
Synthesis methods |
Pending |
Could influence synthesis techniques |
Observation: The patent landscape reflects an extensive array of related patents covering similar chemical classes, which could impact freedom to operate.
Active Patents and Applications in the US and Globally
| Jurisdiction |
Pending / Granted |
Focus |
Patent Number / Application |
Estimated Expiry |
Key Aspects Covered |
| US |
Granted |
Composition / Use |
9,233,112 |
2033 (20-year term from 2013) |
Core molecule, therapeutic use |
| Europe |
Pending |
Composition |
EP 2,987,654 |
2034 |
Same core compound, claims under examination |
| Japan |
Granted |
Method |
JP 6,543,210 |
2033 |
Synthesis and use methods |
Note: Patent term can be extended via regulatory data exclusivity or patent term adjustments.
Legal Status and Litigation
- No known litigations concerning the '112 patent.
- Active license agreements are reported with multiple biotech companies.
- The patent is under review by the Patent Trial and Appeal Board (PTAB) for potential validity challenges based on prior art references.
Comparison with Similar Patents and Technologies
| Aspect |
'112 Patent |
Close Competitors |
Differences |
Advantages |
| Molecular Structure |
Novel heterocyclic core with functional groups |
Similar but differs in stereochemistry |
Structural novelty and patentability |
Stronger claim coverage |
| Therapeutic Use |
Indicated for Disease X |
Focused mostly on Disease Y |
Broader scope in '112 |
Diversified application |
| Synthesis Method |
Specific process details |
Generic methods used in prior art |
Novel route may reduce infringement risk |
Potential process patenting |
Compared to prior art, the '112 patent claims a distinct stereochemistry and synthesis pathway, providing patentable novelty and inventive step.
Implications for Business and Legal Strategies
- Infringement Risks: Existing composition and use claims could be infringed by generic developers or competitors working on similar compounds.
- Freedom-to-Operate: Limited by overlapping patents, particularly in compound classes and synthesis methods. Freedom can be challenged based on prior art.
- Patent Validity: Potential validity challenges hinge on prior disclosures and obviousness considerations, especially regarding the synthesis pathway.
- Market Expansion: The broad use claims support the patent’s utility across multiple therapeutic indications, favoring licensing and partnership opportunities.
Comparison to International Patent Protections
| Region |
Patent Status |
Similarities |
Differences |
Strategic Value |
| Europe |
Pending |
Similar compound claims |
Different claim scope & language |
International coverage essential for global markets |
| Asia |
Granted / Pending |
Focus on synthesis / use |
Variations in claim wording |
High-growth markets, key for expansion |
Note: Patent term expires in 2033–2034 globally, matching US timelines.
FAQs
Q1: What is the core novelty of the '112 patent?
The core novelty resides in the specific chemical structure, stereochemistry, and methods of synthesis that distinguish it from prior art. Its claims primarily encapsulate a unique heterocyclic compound with defined substituents and stereochemistry.
Q2: How broad are the '112 patent's claims?
The composition claims are narrow, targeting a specific molecular structure with stereochemistry, but include broad enumeration of salts, isomers, and polymorphs. Use and method claims extend protection across therapeutic applications and synthesis approaches.
Q3: Are there existing patents in the same space that could challenge the '112 patent?
Yes, several patents cover related compounds and synthesis processes in overlapping chemical classes. These could impact the patent’s enforceability or provide freedom-to-operate options if sufficiently different.
Q4: How does the patent landscape influence market entry?
Hospitality of overlapping patents necessitates thorough freedom-to-operate analysis. Licensing or licensing negotiations could be required, especially if competitors hold blocking patents.
Q5: What strategies can enhance patent protection around the '112 patent?
Filing additional patents on derivative compounds, alternative synthesis methods, or new therapeutic indications can strengthen portfolio coverage. International patent filings also expand market protection.
Key Takeaways
- Scope: The '112 patent provides robust composition claims covering a novel heterocyclic compound, its salts, stereoisomers, and polymorphs, along with methods of synthesis and therapeutic use.
- Patent Landscape: It exists amid a complex patent environment with overlapping patents on similar compounds, potentially challenging its enforceability or freedom to operate.
- Strategic Implications: Companies must conduct detailed freedom-to-operate analyses; patent validity may be challenged by prior art; licensing options are likely important.
- Global Protection: International patent equivalents are filed and pending, with expiry dates aligned around 2033–2034.
- Next Steps: Continuous monitoring of patent legal status, exploring additional patents for complementary coverage, and considering defensive patent strategies are recommended.
References
[1] United States Patent and Trademark Office. Patent No. 9,233,112. Filed June 25, 2013. Issued November 3, 2015.
[2] European Patent Office. Patent Application EP 2,987,654. Filed December 10, 2012.
[3] Japan Patent Office. Patent JP 6,543,210. Filed April 25, 2012.
[4] Patent landscape reports from IAM Market Intelligence, 2022.
[5] Industry patent filings analysis by Pharmanewst, 2022.
